Condition: Open Angle Glaucoma

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Location(s): Jacksonville - Florida Eye Specialist (Gate)

Condition: Ocular Hypertension, Open Angle Glaucoma, Ophthalmology